Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michelle Erbel"'
Autor:
Ellen Gebauer, Wibke Bechtel-Walz, Christoph Schell, Michelle Erbel, Gerd Walz, Tobias Hermle
Publikováno v:
Case Reports in Nephrology and Dialysis, Vol 11, Iss 3, Pp 270-274 (2021)
Immunotherapy using immune checkpoint inhibitors revolutionized therapies for a variety of malignancies. Nivolumab, an antibody blocking programmed cell death 1 protein, and ipilimumab that blocks cytotoxic T-lymphocyte-associated protein 4 effective
Externí odkaz:
https://doaj.org/article/30ba350cb1104f398d457bf92ed14587
Autor:
Pauline van Schouwenburg, Susanne Unger, Kathryn J. Payne, Fabian M. P. Kaiser, Ingrid Pico-Knijnenburg, Jens Pfeiffer, Oliver Hausmann, David Friedmann, Michelle Erbel, Maximilian Seidl, David van Zessen, Andrew P. Stubbs, Mirjam van der Burg, Klaus Warnatz
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Common variable immunodeficiency (CVID), characterized by recurrent infections, low serum class-switched immunoglobulin isotypes, and poor antigen-specific antibody responses, comprises a heterogeneous patient population in terms of clinical presenta
Externí odkaz:
https://doaj.org/article/003fd5f0403547f692216d98a57c9ffd
Autor:
Sarah C. Grünert, Sara Tucci, Anke Schumann, Meike Schwendt, Gwendolyn Gramer, Georg F. Hoffmann, Michelle Erbel, Brigitte Stiller, Ute Spiekerkoetter
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-6 (2020)
Abstract Background Primary carnitine deficiency due to mutations in the SLC22A5 gene is a rare but well-treatable metabolic disorder that puts patients at risk for metabolic decompensations, skeletal and cardiac myopathy and sudden cardiac death. Re
Externí odkaz:
https://doaj.org/article/a26c44baa7784e1ebd0a83e4045d9073
Autor:
Wibke Bechtel-Walz, Gerd Walz, Christoph Schell, Michelle Erbel, Ellen Gebauer, Tobias Hermle
Publikováno v:
Case Reports in Nephrology and Dialysis
Case reports in nephrology and dialysis, 11(3):270-274
Case Reports in Nephrology and Dialysis, Vol 11, Iss 3, Pp 270-274 (2021)
Case reports in nephrology and dialysis, 11(3):270-274
Case Reports in Nephrology and Dialysis, Vol 11, Iss 3, Pp 270-274 (2021)
Immunotherapy using immune checkpoint inhibitors revolutionized therapies for a variety of malignancies. Nivolumab, an antibody blocking programmed cell death 1 protein, and ipilimumab that blocks cytotoxic T-lymphocyte-associated protein 4 effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::121fd75a2af6b230f0e75003943a188c
http://europepmc.org/articles/PMC8460889
http://europepmc.org/articles/PMC8460889